These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8312100)

  • 1. Antimetabolites.
    Chu E; Johnston PG; Takimoto CH; Politi PM; Grem JL; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1993; 14():1-25. PubMed ID: 8312100
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimetabolites.
    Allegra CJ; Baram J; Chabner BA; Yeh GC; Aiba K; Curt GA
    Cancer Chemother Biol Response Modif; 1987; 9():1-22. PubMed ID: 2484324
    [No Abstract]   [Full Text] [Related]  

  • 3. Antimetabolites.
    Johnston PG; Takimoto CH; Grem JL; Fidias P; Grossbard ML; Chabner BA; Allegra CJ; Chu E
    Cancer Chemother Biol Response Modif; 1997; 17():1-39. PubMed ID: 9551206
    [No Abstract]   [Full Text] [Related]  

  • 4. Antimetabolites.
    Chu E; Johnston PG; Grem JL; Takimoto CH; Van Groeningen C; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1994; 15():1-31. PubMed ID: 7779582
    [No Abstract]   [Full Text] [Related]  

  • 5. Antimetabolites.
    Chu E; Grem JL; Johnston PG; Politi PM; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1992; 13():1-30. PubMed ID: 1389906
    [No Abstract]   [Full Text] [Related]  

  • 6. Antimetabolites.
    Johnston PG; Takimoto CH; Grem JL; Chabner BA; Allegra CJ; Chu E
    Cancer Chemother Biol Response Modif; 1996; 16():1-27. PubMed ID: 8639379
    [No Abstract]   [Full Text] [Related]  

  • 7. Antimetabolites.
    Allegra CJ; Grem JL; Chu E; Johnston P; Yeh GC; Chabner BA
    Cancer Chemother Biol Response Modif; 1990; 11():1-28. PubMed ID: 2223392
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer chemotherapy and biological response modifiers annual 16. Introduction.
    Pinedo HM; Longo DL; Chabner BA
    Cancer Chemother Biol Response Modif; 1996; 16():xvii-xviii. PubMed ID: 8639378
    [No Abstract]   [Full Text] [Related]  

  • 9. Antimetabolites.
    Grem JL; Takimoto CH; Multani P; Chu E; Ryan D; Chabner BA; Allegra CJ; Johnston PG
    Cancer Chemother Biol Response Modif; 1999; 18():1-38. PubMed ID: 10800475
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the effects of several inhibitors of the synthesis of nucleic acids upon the viability and progression through the cell cycle of cultured H. Ep. no. 2 cells.
    Wheeler GP; Bowdon BJ; Adamson DJ; Vail MH
    Cancer Res; 1972 Dec; 32(12):2661-9. PubMed ID: 4264728
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antimetabolites in the treatment of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. II].
    Grignani F; Martelli M; Tonato M
    Clin Ter; 1974 Apr; 69(2):153-76. PubMed ID: 4134598
    [No Abstract]   [Full Text] [Related]  

  • 12. Antimetabolites.
    Schornagel JH
    Curr Opin Oncol; 1989 Dec; 1(2):179-85. PubMed ID: 2489957
    [No Abstract]   [Full Text] [Related]  

  • 13. [5-fluorouracil: metabolism and current indications in digestive cancer treatment].
    Aparicio T; Ducreux M; Chaussade S
    Gastroenterol Clin Biol; 2002 Jan; 26(1):38-47. PubMed ID: 11938038
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells.
    Wilkoff LJ; Wilcox WS; Burdeshaw JA; Dixon GJ; Dulmadge EA
    J Natl Cancer Inst; 1967 Nov; 39(5):965-75. PubMed ID: 6071005
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC.
    Maier S; Strasser S; Saiko P; Leisser C; Sasgary S; Grusch M; Madlener S; Bader Y; Hartmann J; Schott H; Mader RM; Szekeres T; Fritzer-Szekeres M; Krupitza G
    Apoptosis; 2006 Mar; 11(3):427-40. PubMed ID: 16538382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimetabolites.
    Grem JL; Chabner BA; Chu E; Johnson P; Yeh GC; Allegra CJ
    Cancer Chemother Biol Response Modif; 1991; 12():1-25. PubMed ID: 1834143
    [No Abstract]   [Full Text] [Related]  

  • 17. Resistance mechanisms to methotrexate in tumors.
    Bertino JR; Göker E; Gorlick R; Li WW; Banerjee D
    Stem Cells; 1996 Jan; 14(1):5-9. PubMed ID: 8820944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
    Cole PD; Smith AK; Kamen BA
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):111-6. PubMed ID: 12172974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.
    Jiang H; Lu J; Jiang J; Hu P
    J Clin Pharmacol; 2004 Nov; 44(11):1260-72. PubMed ID: 15496644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate.
    Held-Warmkessel J
    Clin J Oncol Nurs; 2000; 4(4):187-8. PubMed ID: 11261104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.